Follicum has recruited Susanne Scheele to the position of Project Manager for the company’s diabetes project. Susanne will commence her new role in January 2018.
Susanne Scheele has extensive experience from both the pharmaceutical industry and academic research institutions including Lund and Uppsala Universities. Her previous positions include that of Senior Scientist at Novo Nordisk A/S in Denmark, where she worked on the development of oral GLP-1 analogues in the field of diabetes. Susanne holds a PhD in Medical Sciences from Lund University. At Follicum, Susanne will be responsible for the preclinical development of FOL-014 in the field of diabetes.
CEO Jan Alenfall comments
– Susanne brings valuable experience in the development of peptide-based diabetes therapeutics, which is of significant importance for Follicum’s diabetes project. By recruiting Susanne, the company has now acquired the necessary expertise to be able to focus its work with the pre-clinical development programme towards the development of a drug candidate against diabetes. We wish Susanne a very warm welcome to Follicum!
For more information, please contact:
Jan Alenfall – CEO, Follicum AB
Phone: 046 – 19 21 97
About Follicum AB
Follicum is a biotech company focused on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, the drug candidate FOL-014 has demonstrated an increase in insulin release in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Aktietorget since 2014. www.follicum.com